Advertisement

Featured in NEJM Journal Watch: Updated Guidelines for HER2 Testing in Breast Cancer — Physician’s First Watch

Medical News |
November 8, 2013

Featured in NEJM Journal Watch: Updated Guidelines for HER2 Testing in Breast Cancer

By the NEJM Journal Watch Editors

The guidelines carry recommendations for oncologists and pathologists. In NEJM Journal Watch, oncologist William Gradishar comments: "The availability of more human epidermal growth factor receptor 2-targeted therapies for breast cancer makes it imperative that HER2 testing is optimally performed and interpreted to give patients the best therapy options."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement